European journal of pharmacology · 2026
PEGylated cerium oxide nanoparticles alleviate osteoarthritis progression by inhibiting chondrocyte ferroptosis and maintaining cartilage homeostasis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Huajie, Zhuang Huangming, Zhou Panghu
Аннотация
BACKGROUND: Osteoarthritis (OA) is a prevalent degenerative joint disease characterized by disruption of articular cartilage homeostasis, with ferroptosis of chondrocytes playing a crucial role. Cerium oxide nanoparticles (CeONPs), a class of inorganic nanozymes, exhibit potent antioxidant and anti-inflammatory properties. However, their effects on OA chondrocytes remain poorly understood.
METHODS: mPEG2k-DSPE was employed to facilitate the transfer of CeONPs into the aqueous phase, resulting in PEG-CeONPs. Primary chondrocytes were isolated and subjected to erastin treatment to induce ferroptosis. The impact of PEG-CeONPs on oxidative stress, Fe2+ concentrations, mitochondrial dysfunction, ferroptosis-associated proteins, and OA-related catabolic phenotypes was evaluated. Additionally, the involvement of NRF2 in ferroptosis and its chondroprotective effects were investigated using NRF2-siRNA. An experimental OA model was established in rats through anterior cruciate ligament transection.
RESULTS: Our study demonstrated that PEG-CeONPs attenuated erastin-induced cytotoxicity and reduced oxidative stress in chondrocytes. Moreover, PEG-CeONPs inhibited erastin-induced ferroptosis and promoted collagen matrix synthesis and secretion. The protective effects of PEG-CeONPs were mediated by the NRF2 pathway, as NRF2 silencing via siRNA significantly diminished the anti-ferroptosis and chondroprotective effects of PEG-CeONPs in vitro. These findings were further validated in OA rat models, where PEG-CeONPs treatment led to a reduction in ferroptosis-related gene expression and significantly alleviated cartilage degradation.
CONCLUSIONS: This study elucidates the previously unexplored relationship between PEG-CeONPs and ferroptosis in OA chondrocytes. PEG-CeONPs demonstrate anti-ferroptosis and chondroprotective effects by activating the NRF2 pathway, suggesting their potential as therapeutic agents for OA.
METHODS: mPEG2k-DSPE was employed to facilitate the transfer of CeONPs into the aqueous phase, resulting in PEG-CeONPs. Primary chondrocytes were isolated and subjected to erastin treatment to induce ferroptosis. The impact of PEG-CeONPs on oxidative stress, Fe2+ concentrations, mitochondrial dysfunction, ferroptosis-associated proteins, and OA-related catabolic phenotypes was evaluated. Additionally, the involvement of NRF2 in ferroptosis and its chondroprotective effects were investigated using NRF2-siRNA. An experimental OA model was established in rats through anterior cruciate ligament transection.
RESULTS: Our study demonstrated that PEG-CeONPs attenuated erastin-induced cytotoxicity and reduced oxidative stress in chondrocytes. Moreover, PEG-CeONPs inhibited erastin-induced ferroptosis and promoted collagen matrix synthesis and secretion. The protective effects of PEG-CeONPs were mediated by the NRF2 pathway, as NRF2 silencing via siRNA significantly diminished the anti-ferroptosis and chondroprotective effects of PEG-CeONPs in vitro. These findings were further validated in OA rat models, where PEG-CeONPs treatment led to a reduction in ferroptosis-related gene expression and significantly alleviated cartilage degradation.
CONCLUSIONS: This study elucidates the previously unexplored relationship between PEG-CeONPs and ferroptosis in OA chondrocytes. PEG-CeONPs demonstrate anti-ferroptosis and chondroprotective effects by activating the NRF2 pathway, suggesting their potential as therapeutic agents for OA.